Alpha Cancer Technologies Presents New Data from ACT-903, an AFP-Maytansine Conjugate, in Online Publication at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
The ASCO meeting will take place in Chicago from June 2-6, 2023.
- The ASCO meeting will take place in Chicago from June 2-6, 2023.
- Now across multiple tumor models, we have observed high activity in treatment groups including statistically significant dose-dependent reduction in tumor volume and increased survival.
- The research used an ovarian xenograft model compared to control with four dosing regimens of the AFP-maytansine conjugate, ACT-903.
- ACT plans to submit an Investigational New Drug (IND) application for ACT-903 in 2024.